The Bay Area Breast Cancer SPORE renewal application focuses on unmet needs in two areas - improved management of premalignant disease and more effective treatment of invasive cancer subtypes that do not respond well to current therapeutic strategies and that are at high risk of metastasis. Our approach is based on the increasingly well-established concept that breast cancer is a heterogeneous disease in which molecularly defined subsets progress and respond differentially to therapy. Work proposed in this renewal application will be carried out in four projects: Project 1 - Risk Stratification for Subsequent Tumors in Women with DCIS will test the hypothesis that the molecular events discovered to be important in early breast cancer development during the last project period will be associated with risk of subsequent progression of DCIS to invasive cancer. Project 2 - Genomic Approaches to Breast Cancer Subsets Identification and Treatment will identify FDA approved and experimental drugs that are effective against basal and luminal/amplifier breast cancer subtypes, develop molecular marker assays to guide the clinical introduction of these drugs and explore the molecular mechanisms through which effective drugs operate. Project 3 - Nanoparticle-based Chemotherapy against Aggressive Breast Cancer Subtypes will develop lipidic nanoparticle-based therapies immunologically targeted to aggressive breast cancer phenotypes, with particular emphasis on treatment of basal-like tumors. Project 4 - Breast Cancer Therapeutic Agents Based on Telomerase Misfunction will continue to develop a nucleic acid construct to knock down expression of endogenous human telomerase RNA (siRNA against hTer) and introduce mutant-template hTer (MT-hTer) to force synthesis of mutant telomeres thereby inducing a rapid DMA damage response with telomere uncapping and apoptosis. These projects will supported by cores for Administration, Tissue and Outcomes, Biostatistics, Bioinformatics. In addition, an Advocacy Core infuses relevant patient experiences into the SPORE, addresses recurrent barriers to translational research, and networks with various organizations throughout the Bay Area and nationally.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058207-18
Application #
8250847
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (O1))
Program Officer
Kuzmin, Igor A
Project Start
1997-08-01
Project End
2013-11-30
Budget Start
2012-01-20
Budget End
2013-11-30
Support Year
18
Fiscal Year
2012
Total Cost
$2,300,000
Indirect Cost
$761,225
Name
University of California San Francisco
Department
Pathology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Cope, Leslie M; Fackler, Mary Jo; Lopez-Bujanda, Zoila et al. (2014) Do breast cancer cell lines provide a relevant model of the patient tumor methylome? PLoS One 9:e105545
Province, M A; Goetz, M P; Brauch, H et al. (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95:216-27
Wolf, Denise M; Lenburg, Marc E; Yau, Christina et al. (2014) Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. PLoS One 9:e88309
Iglesia, Michael D; Vincent, Benjamin G; Parker, Joel S et al. (2014) Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res 20:3818-29
Oates, Chris J; Dondelinger, Frank; Bayani, Nora et al. (2014) Causal network inference using biochemical kinetics. Bioinformatics 30:i468-74
Zhao, Lequn; Qu, Liang; Zhou, Jing et al. (2014) High throughput identification of monoclonal antibodies to membrane bound and secreted proteins using yeast and phage display. PLoS One 9:e111339
Listerman, Imke; Gazzaniga, Francesca S; Blackburn, Elizabeth H (2014) An investigation of the effects of the core protein telomerase reverse transcriptase on Wnt signaling in breast cancer cells. Mol Cell Biol 34:280-9
Chaluvally-Raghavan, Pradeep; Zhang, Fan; Pradeep, Sunila et al. (2014) Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. Cancer Cell 26:863-79
Cureton, Elizabeth L; Yau, Christina; Alvarado, Michael D et al. (2014) Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol 21:2889-96
Zawadzka, Anna M; Schilling, Birgit; Cusack, Michael P et al. (2014) Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. Mol Cell Proteomics 13:1034-49

Showing the most recent 10 out of 288 publications